Surgical Efficacy and Safety of Patients with Locally Advanced Gastric Cancer following Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy

Table 1

Patient characteristics at diagnosis and treatment ().

Characteristic	CCRT ()	Chemotherapy ()
Median age (years)	64.0	71.0	0.459
Gender (M : F)	27 : 11	15 : 10	0.419
Tumor invasion			0.277
cT3 or cT4a	23	19
cT4b	15	6
Lymph node metastasis			0.741
cN0 or cN1	6	5
≧cN2	32	20
cStage			0.277
III	23	19
IVA	15	6
Chemotherapy regimen
FOLFOX4	33	19
Cisplatin+5-FU	1	0
XELOX	1	2
Xeloda only	0	1
Gemcitabine+S-1	1	0
FLOT	2	3

TNM staging classification for carcinoma of the stomach (American Joint Committee on Cancer, AJCC 8^th ed., 2017). FOLFOX: folinic acid+fluorouracil+oxaliplatin; 5-FU: 5-fluorouracil; XELOX: capecitabine+oxaliplatin; Xeloda: capecitabine; S-1: tegafur/gimeracil/oteracil; FLOT: fluorouracil+folinic acid+oxaliplatin+docetaxel.